Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040034/S040

DuraSeal Dural Sealant System

Integra LifeSciences Corporation · Decision date Dec 17, 2025

FDA DECISIONP040034/S040

What did the FDA decide?

FDA records P040034/S040 as a supplement to PMA P040034, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 17, 2025.

FDA approval order statement

addition of an external supplier for in-process PBS solution
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Dec 17, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P040034/S040
Regulatory pathway
PMA supplement
Product code
NQR
Decision code
OK30
Decision date
Dec 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Product code
NQR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040034/S040 received

    Application receipt date recorded by FDA.

  2. P040034/S040 · FDA decision

    30-Day Notice

  3. P040034/S041 · Related supplement

    DuraSeal Dural Sealant System

Timeline entries are records held by MedtechLedger for P040034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040034

Product / regulatory recordCompanyPathwayDecision dateSource
Integra LifeSciences CorporationPMA supplementFeb 27, 2026FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA supplementAug 31, 2026FDA
Pramand, LLCPMA supplementAug 5, 2026FDA
Stryker Leibinger GmbH & Co. KGPMA supplementJul 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integra LifeSciences Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
311 Enterprise Dr., Planisboro, NJ, 08536

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records